Alain Algazi MD

Oncology•San Francisco, CA

Assistant Professor, Medicine, University of California, San Francisco, School of

Join to View Full Profile

505 Parnassus Ave # M1286Box 1270San Francisco, CA 94143
Phone+1 415-476-0624

Education & Training

University of California (San Francisco)Fellowship, Hematology and Medical Oncology, 2007 - 2010
UCLA David Geffen School of Medicine/UCLA Medical CenterResidency, Internal Medicine, 2004 - 2007
David Geffen School of Medicine at UCLAClass of 2004

Certifications & Licensure

CA State Medical License 2006 - 2026
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013

Clinical Trials

BKM120 Combined With Vemurafenib (PLX4032) in BRAFV600E/K Mutant Advanced Melanoma Start of enrollment: 2012 Jun 09
Completed
Phase 1, Phase 2
Dabrafenib and Trametinib With Radiosurgery in Melanoma Brain Mets Start of enrollment: 2013 Apr 01
Terminated
Phase 2
Phase II Study of Radiation Therapy and Vismodegib for Advanced Head/Neck Basal Cell Carcinoma Start of enrollment: 2013 May 01
Completed
Phase 2
Trametinib With GSK2141795 in BRAF Wild-type Melanoma Start of enrollment: 2013 Sep 10
Completed
Phase 2
Dabrafenib and Trametinib for the Treatment of Patients With Stage III-IV BRAF Mutant Melanoma That Cannot Be Removed by Surgery Start of enrollment: 2014 Sep 19
ACTIVE_NOT_RECRUITING
PHASE2
Trial of pIL-12/MK-3475 in Metastatic Melanoma Start of enrollment: 2015 Aug 17
Completed
Phase 2
Efficacy Study of Pembrolizumab in Relapsed, Locally Recurrent Squamous Cell Cancer of the Head and Neck Start of enrollment: 2016 Jul 06
ACTIVE_NOT_RECRUITING
PHASE2
Preoperative Immunotherapy in Patients with Squamous Cell Carcinoma of the Head and Neck Start of enrollment: 2019 Mar 08
RECRUITING
PHASE2
Pepinemab in Combination With Pembrolizumab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Start of enrollment: 2021 Aug 09
COMPLETED
PHASE1, PHASE2
Roles: Contact
Join now to see all

Publications & Presentations

PubMed

Comparative Analysis of Intracranial Response Assessment Criteria in Patients With Melanoma Brain Metastases Treated With Combination Nivolumab + Ipilimumab in CheckMa...
Raymond Y Huang, Gilbert Youssef, Thomas Nelson, Patrick Y Wen, Peter Forsyth
Journal of Clinical Oncology. 2025-04-01
CRE25-035: Vascular Endothelial Growth Factor Inhibitor-Induced Radiation Recall Tracheitis in a CASTLE Carcinoma of the Thyroid Patient.
Sahithee Alekhya Batchu, Yue Ma, Sue Yom, Chase Heaton, Alain Algazi
Journal of the National Comprehensive Cancer Network. 2025-03-28
1 citations
Neutrophil-to-Lymphocyte Ratio and Pembrolizumab Outcomes in Oral Cavity Squamous Cell Carcinoma.
Angeline A Truong, Rex H Lee, Xin Wu, Alain P Algazi, Hyunseok Kang
Otolaryngology--Head and Neck Surgery. 2025-02-01

Journal Articles

Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain
Kim Margolin, Alain Algazi, Omid Hamid, Christopher D Lao, Anna C Pavlick, Michael A Postow, F Stephen Hodi, Nikhil I Khushalani, Marc S Ernstoff, Hussein A Tawbi, Igo..., The New England Journal of Medicine

Press Mentions

Leaving Lymph Nodes Intact Could Increase Efficacy of Cancer ImmunotherapyApril 12th, 2023
Sequential-Combinatorial Regimens Can Make Treatment More Effective for People with Aggressive CancersAugust 12th, 2021
Sensei Biotherapeutics Announces New Clinical Data from the Ongoing Phase 1/2 Combination Trial of SNS-301 in Patients with Squamous Cell Carcinoma of the Head and NeckMay 19th, 2021
Join now to see all